SoundHealth has raised $12.3M in a Series A round backed by ShangBay Capital, a bet on AI-driven respiratory care that skips the pharmacy aisle entirely. The startup’s pitch is straightforward: a wearable, drug-free alternative for the millions who suffer from nasal congestion.
That device, called SONU, is already FDA-authorized and claims to be the first of its kind-a wearable that delivers personalized relief without sprays or medication. SoundHealth’s founders come from serial stints in both tech and medicine, which may explain the hybrid approach. The fresh capital gives them runway to push SONU further, though specifics on expansion plans weren’t disclosed.
